Management of Acute Pancreatitis

Acute pancreatitis (AP) is an inflammatory condition of the pancreas that can range from a mild, selflimiting disease to a severe, lifethreatening illness with systemic complications. Early recognition and timely, evidencebased management are essential to reduce morbidity and mortality.

1. Initial Assessment

• Clinical presentation: Sudden epigastric pain radiating to the back, nausea, vomiting.
• Vital signs: Look for fever, tachycardia, hypotension, and signs of systemic inflammatory response syndrome (SIRS).
• Laboratory tests: Serum amylase and lipase (3 ULN), complete blood count, electrolytes, renal and liver function tests, Creactive protein (CRP), and calcium.
• Imaging: Abdominal ultrasound (to assess gallstones) and contrastenhanced CT (if diagnosis is uncertain or patient deteriorates).
• Severity scores: Use at least one scoring system (Ranson, Glasgow, APACHEII, BISAP) within the first 24hours to predict severity.

2. Immediate Management

2.1 Fluid Resuscitation

Aggressive intravenous fluid therapy is the cornerstone of early treatment.

• Goal: 250500mL/h of isotonic crystalloid (e.g., lactated Ringers) for the first 1224h.
• Target urine output0.5mL/kg/h, MAP65mmHg, and hematocrit stabilization.
• Adjust based on cardiac status, renal function, and ongoing losses.

2.2 Pain Control

Effective analgesia improves respiratory mechanics and reduces stress response.

• Intravenous opioids (e.g., morphine, hydromorphone) are firstline.
• Consider patientcontrolled analgesia (PCA) for better titration.
• Avoid excessive sedation that could impair cough and deep breathing.

2.3 Nutritional Support

Early enteral nutrition is preferred over nil per os (NPO) after the initial 24h.

• Start oral feeding as soon as the patient tolerates liquids.
• If oral intake is not possible, place a nasogastric or nasojejunal tube for feeding.
• Parenteral nutrition only when enteral route is contraindicated.

2.4 Management of Underlying Etiology

• Biliary pancreatitis: Early (<24h) endoscopic retrograde cholangiopancreatography (ERCP) for cholangitis or persistent bile duct obstruction.
• Alcoholrelated pancreatitis: Counsel on abstinence; consider referral for addiction services.
• Hypertriglyceridemia: Insulin infusion or apheresis if triglycerides >1000mg/dL.
• Druginduced: Discontinue offending agent.

3. Monitoring and Ongoing Care

3.1 Clinical Monitoring

• Vitals every 46h during the acute phase.
• Hourly urine output; daily weight.
• Serial abdominal examinations for worsening tenderness or distension.

3.2 Laboratory Monitoring

3.3 Imaging Followup

Repeat contrastenhanced CT is indicated if the patient deteriorates after 4872h or if necrosis is suspected.

4. Management of Complications

4.1 Pancreatic Necrosis

• Sterile necrosis: Conservative management with antibiotics only if infection is proven.
• Infected necrosis: Early (within 1week) minimally invasive drainage (percutaneous, endoscopic, or surgical) guided by imaging.
• Stepup approach is preferred over immediate open necrosectomy.

4.2 Fluid Collections

• Pseudocyst >6weeks, symptomatic, or >5cm: Drainage (endoscopic transpapillary or transgastric, percutaneous, or surgical).
• Acute peripancreatic fluid collections (4weeks): Usually selflimited, monitor.

4.3 Systemic Complications

• Acute respiratory distress syndrome (ARDS): Lungprotective ventilation, early mobilization.
• Renal failure: Optimize volume status, avoid nephrotoxic drugs, consider renal replacement therapy.
• Cardiovascular shock: Vasopressors (norepinephrine) after adequate fluid resuscitation.
• Coagulopathy: Correct with plasma, vitamin K, or factor concentrates as needed.

5. Discharge Planning and LongTerm Care

• Patients with mild, resolved disease may be discharged when pain is controlled, oral intake is adequate, and labs are stable.
• Provide clear instructions on followup imaging (usually at 46weeks) to assess resolution of collections.
• Address etiology: cholecystectomy for gallstone disease (usually during the same admission), alcohol cessation programs, lipidlowering therapy for hypertriglyceridemia.
• Vaccinate against pneumococcus and influenza in patients with splenic dysfunction or immunosuppression.
• Educate on warning signs (recurrent pain, fever, jaundice) requiring urgent attention.

6. Key Points Summary